NPNuri Peker

Nuri Peker

*This is an algorithmically generated author record based on publicly available information.

Nuri Peker has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Relationship between pre-micro-TESE serum anti-Müllerian hormone (AMH) levels and sperm retrieval success in patients diagnosed with non-obstructive azoospermia: A retrospective study

    by Ayşen Yücetürk, Nuri Peker, Özge Karaosmanoğlu, Tansu Güdelci, Burak Elmas, İlKe Özer Aslan, Bülent Tıraş

    Relationship between pre-micro-TESE serum anti-Müllerian hormone (AMH) levels and sperm retrieval success in patients diagnosed with non-obstructive azoospermia: A retrospective study - Turkish Journal of Obstetrics and Gynecology

  • Comparison of embryological and clinical outcomes of ICSI cycles using ejaculated versus testicular sperm (TESA/mTESE) in men with cryptozoospermia: A retrospective cohort study

    by Ayşen Yücetürk, Nuri Peker, Özge Karaosmanoğlu, Burak Elmas, İlKe Özer Aslan, Tansu Güdelci, Bülent Tıraş

    Comparison of embryological and clinical outcomes of ICSI cycles using ejaculated versus testicular sperm (TESA/mTESE) in men with cryptozoospermia: A retrospective cohort study - Turkish Journal of Obstetrics and Gynecology

  • Open Access

    Embryos derived from small follicles (<8 mm) exhibit delayed blastulation: a retrospective time-lapse analysis

    by Nuri Peker, Ayşen Yücetürk, Özge Karaosmanoğlu, Burak Elmas, İlKe Özer Aslan, Bülent Tıraş

    Background: Oocytes from small follicles are frequently discarded, although they may represent an additional resource in patients with few available oocytes. This study aimed to evaluate whether blastocysts derived from follicles <8 mm exhibit altered morphokinetic patterns compared with those from larger follicles. Methods: This retrospective study analyzed 62 blastocysts from 18 women undergoing ICSI: 20 from follicles <8 mm and 42 from follicles ≥11 mm. Morphokinetic parameters (tPNa-tB) were recorded by time-lapse monitoring. As several women contributed to both groups, linear mixed models with a random intercept for patient accounted for clustering. Oocyte- and embryo-level rates were compared using generalized estimating equations with patient as the clustering variable. Results: No between-group differences were observed for tPNa, tPNf or t2–t8. tSB occurred later in the <8 mm group (median 101.2 vs 95.3 h; p = 0.001), as did tB (108.1 vs 104.3 h; p=0.004). Differences persisted after accounting for within-patient clustering (tSB β = 7.91 h; tB β=8.29 h; both p<0.001). Day-5 blastocyst formation per fertilized oocyte was lower in the <8 mm group (28.8% vs 49.3%; p = 0.040), whereas overall blastocyst formation (38.5% vs 56.5%; p = 0.105) and day-6 rates (9.6% vs 7.2%; p = 0.683) did not differ significantly after accounting for within-patient clustering. Euploidy rates did not differ significantly between blastocysts derived from follicles <8 mm (5/10, 50.0%) and ≥11 mm (7/23, 30.4%; p = 0.433), although the number of biopsied embryos was small. Frozen-thawed single embryo transfer of two euploid blastocysts derived from follicles <8 mm resulted in two live births. Conclusions: Follicle size is associated with the timing of blastocyst development, with embryos from smaller follicles showing an approximately 8-hour delay in blastulation. Day-6 blastocyst rates and euploidy rates did not differ significantly between groups. These exploratory findings suggest that delayed blastulation alone should not be taken as evidence of impaired developmental potential in embryos derived from small follicles.

  • Intrauterine fluid during frozen embryo transfer preparation: Impact of etiology, treatment, and fluid dimension on pregnancy outcomes

    by Merve Ecem Albayrak, Nuri Peker, Özge Karaosmanoğlu, Ömür Albayrak, Ayşen Yücetürk, İlKe Özer Aslan, Burak Elmas, Eser Çolak, Bülent Tıraş

  • Open Access

    Clinical outcomes of 1PN- and 3PN-derived blastocysts in the absence of transferable 2PN embryos: A retrospective analysis

    by Nuri Peker, Ayşen Yücetürk, Esra Tığlı, Özge Karaosmaoğlu, Burak Elmas, İlKe Özer Aslan, Bülent Tıraş

    Objective: We aimed to determine the blastocyst formation rates, preimplantation genetic testing for aneuploidy (PGT-A) results, and pregnancy rates of embryos derived from 1pronucleus (1PN) and 3 pronuclei (3PN). Methods: A total of 150 patients who developed 1PN and/or 3PN embryos were enrolled in the study. The embryos were divided into three groups according to the number of pronuclei: group (i) consisted of 1PN embryos; group (ii) consisted of 3PN embryos; and group (iii) was the control group, which included 2PN embryos. The primary outcomes were the blastocyst formation rate and euploidy rate of the 1PN and 3PN embryos. The secondary outcomes were pregnancy and live birth rates after embryo transfer. Results: A total of 1711 (72.1%) metaphase II (MII) oocytes were obtained among 2373 oocytes. A total of 508 day-5 embryos developed, of which 44 (8.7%) were identified as 3PN, 13 (2.6%) as 1PN, and 451 (88.8%) as 2PN. PGT-A was performed on 23 3PN embryos and 4 1PN embryos. Overall comparison revealed a significant difference among groups (chi-square (χ²) = 51.11, df = 2, p < 0.0001). In pairwise analyses, 1PN zygotes had significantly lower blastocyst formation rates than both 2PN and 3PN zygotes (both p < 0.0001), whereas the difference between 2PN and 3PN zygotes was not significant (p = 0.5025). All tested blastocysts were reported as aneuploid and none of these embryos were transferred. A total of five 3PN blastocyst transfers were performed in five patients, one 1PN blastocyst transfer was performed in one patient, and combined 1PN and 3PN blastocyst transfer was performed in one patient. Importantly, no preimplantation genetic testing for aneuploidy (PGT-A) was performed on the embryos selected for transfer, and all transfers were carried out without genetic testing. The only pregnancy was achieved in the patient who underwent combined transfer of 1PN and 3PN blastocysts. Conclusion: Blastocyst formation and pregnancy rates derived from abnormally fertilized embryos are low; however, transfer of blastocysts derived from 1PN and 3PN embryos may be considered in patients who do not develop transferable 2PN blastocysts.

  • Open Access

    Prognostic role of endometrial pattern compared with thickness and estradiol in euploid HRT-FET cycles

    by Nuri Peker, Ayşen Yücetürk, Esra Tığlı, Özge Karaosmanoğlu, Burak Elmas, İlKe Özer Aslan, Bülent Tıraş

    Background: Do endometrial pattern types show an association with clinical outcomes in an IVF-ET cohort with pattern diversity, and do endometrial thickness and serum E 2 and P 4 levels measured on the day of endometrial assessment provide additional predictive value regarding reproductive outcomes? Methods: This retrospective HRT-FET study included 237 euploid blastocyst transfer cycles. The effects of endometrial pattern types (Type A–B–C) on pregnancy, miscarriage, and live birth were evaluated; the relationship between endometrial thickness and hormonal parameters and reproductive outcomes was analyzed; and predictive performance was assessed. Results: Significant differences were observed between endometrial pattern types for total pregnancy, biochemical pregnancy, miscarriage, and live birth rates ( p = 0.004), with Type A showing the highest live birth rate. Endometrial thickness did not differ across pattern groups ( p = 0.3819) or pregnancy outcome ( p = 0.5676). Thickness categories showed significant distribution difference ( p = 0.014), with higher live birth rates in >10.1 mm. ROC analyses indicated no predictive value for endometrial thickness in pregnancy (AUC = 0.505; cut-off 8.75 mm) or live birth (AUC = 0.5103; cut-off 11.85mm). E 2 and P 4 levels did not differ between pattern types (E 2 p = 0.3819 and p = 0.2646; P 4 p = 0.0799 and p = 0.2928), and ROC analyses for E 2 showed limited predictive power in Type A (AUC = 0.5505; cut-off 279.5pg/ml) and Type B (AUC = 0.5382; cut-off 369.5pg/ml). Conclusions: Endometrial pattern may be associated with clinical outcomes, whereas endometrial thickness and serum E 2 levels demonstrated limited discriminatory power. These findings highlight the heterogeneity in the existing literature and indicate that their role in decision-making during HRT-FET cycles should be reconsidered.

  • Open Access

    Evaluating progestin-primed and GnRH antagonist ovarian stimulation protocols in PGT-A cycles: implications for clinical practice

    by Burak Elmas, Ozge Karaosmanoglu, Aysen Yuceturk, Ilke Ozer Aslan, Burcu Aksu Turan, Nuri Peker, Omur Albayrak, Hakan Berkil, Bulent Tiras

    Progestin-primed ovarian stimulation (PPOS) has emerged as an alternative to GnRH-antagonist protocols in IVF, yet its impact on embryo chromosomal competence remains controversial. Evidence is particularly limited regarding whether PPOS influences blastocyst euploidy rates and key clinical outcomes in PGT-A cycles, and whether these effects vary according to maternal age and ovarian reserve status. This retrospective cohort study included 1,843 PGT-A cycles (666 PPOS, 1,177 GnRH antagonist) performed at a single tertiary IVF center between January 2016 and January 2024. Controlled ovarian stimulation was performed with either oral medroxyprogesterone acetate or daily cetrorelix, followed by vitrification of all biopsied blastocysts and subsequent frozen embryo transfer. Primary outcomes were blastocyst euploidy and clinical pregnancy rates. Secondary outcomes included embryological parameters, miscarriage, live birth, and cumulative pregnancy rates. Subgroup analyses were performed according to maternal age and ovarian reserve. The mean age was 37.64±4.48 years in the PPOS group and 37.80±3.49 years in the GnRH-antagonist group; age and other baseline characteristics were comparable between groups. PPOS cycles had a shorter stimulation duration (median 8 vs. 9 days, p = 0.001), with comparable gonadotropin requirements and embryological outcomes. Euploidy (32.6% vs. 32.1%, p = 0.653), mosaicism, and aneuploidy rates did not differ significantly. Clinical pregnancy, live birth, and cumulative pregnancy rates were equivalent. PPOS and GnRH antagonist protocols yield comparable embryological and clinical outcomes in PGT-A cycles, including in advanced maternal age and diminished ovarian reserve subgroups. With its shorter stimulation duration and cost-effectiveness, PPOS is a valid alternative when fresh transfer is not planned.


  • Open Access

    Delayed initiation of GnRH antagonist in PCOS patients undergoing IVF: a retrospective cohort study of premature ovulation and embryological outcomes

    by Nuri Peker, Ayşen Yücetürk, Esra Tığlı, Özge Karaosmanoğlu, Burak Elmas, İlKe Özer Aslan, Bülent Tıraş

    We aimed to evaluate whether delayed initiation of gonadotropin hormone-releasing hormone (GnRH) antagonist treatment affects premature ovulation and the number of good-quality blastocysts. We retrospectively reviewed the medical records of polycystic ovary syndrome (PCOS) patients who underwent in vitro fertilization (IVF) treatment at our clinic between 2017 and 2025. Patients were divided into two groups: Group 1: Patients in whom GnRH antagonist injections were initiated when at least three dominant follicles measured ≥17 mm. Group 2: Patients in whom GnRH antagonist was initiated upon identification of a single dominant follicle reaching ≥14 mm. The groups were compared in terms of premature ovulation, estradiol (E2) level at GnRH antagonist initiation, total number of retrieved oocytes, number and proportion of metaphase II (MII) oocytes, fertilization rate, blastocyst number and rate, and good-quality blastocyst grades. A total of 89 patients were included in the study. Of these, 38 patients were assigned to Group 1 and 51 to Group 2. There were no statistically significant differences in age or body-mass index (BMI) between the groups. Serum E2 levels at GnRH antagonist initiation were significantly higher in Group 1. The "median-(Interquartile Range (IQR))" total oocyte count was 33 (27-41) in Group 1 and 30 (26-40) in Group 2. The median 2PN count was 19.5 (12.75-27) in Group 1 and 19.0 (15-22) in Group 2. There were no statistically significant differences between the groups in terms of MII oocyte or two pronuclei (2PN) count. Blastocyst outcomes were comparable between the groups; the median number of day 5-6 blastocysts was 7.0 (IQR: 5-11.5) in Group 1 and 8.0 (IQR: 5-11) in Group 2. Furthermore, the median number of Grade A blastocysts was 4.0 (IQR: 3-10) in Group 1 and 5.0 (IQR: 4-8) in Group 2, and there was no statistically significant difference between the groups regarding Grade‑A blastocyst counts. No premature ovulation occurred in either group. In this PCOS cohort, delayed GnRH antagonist initiation was not associated with impaired laboratory embryological outcomes or increased premature ovulation risk. Prospective randomized controlled trials are needed to confirm these preliminary findings.

  • Open Access

    Pregnancy outcomes following hysteroscopic myomectomy in infertile patients with FIGO type 0–II fibroids: a retrospective study

    by Nuri Peker, Özge Karaosmanoğlu, Ömür Albayrak, Ayşen Yücetürk, İlKe Özer Arslan, Burak Elmas, Bülent Tıraş

    Background: We aimed to evaluate the feasibility and safety of hysteroscopic myomectomy (HM) in infertile patients with International Federation of Gynecology and Obstetrics (FIGO) Type 0, I, and II uterine fibroids. Methods: This study included infertile patients with FIGO type 0, I, and II uterine fibroids who underwent HM before embryo transfer. After surgery, an intrauterine device (IUD) was placed in the uterine cavity, and an adhesion barrier gel was applied. Two months later, the IUD was removed and a control hysterosalpingography (HSG) was performed. Embryo transfer was carried out in patients without suspected intrauterine adhesions (IUA) on HSG. The primary outcomes were clinical pregnancy and live birth rates, and the secondary outcomes were the complication rate and the incidence of IUA. Results: Fifty patients were included. Overall, 39 (78%) conceived, and 21 (42%) achieved a live birth. Second-look hysteroscopy was performed in 4 (8%) patients due to suspected IUA. All four patients subsequently conceived; two had a live birth and two had a biochemical pregnancy. Three patients underwent repeat HM because of new myoma formation. After the second HM, HSG showed no IUA in one patient; embryo transfer was performed, but pregnancy was not achieved. In another patient, IUA were detected; hysteroscopic adhesiolysis was performed, and subsequent evaluation showed no IUA, yet pregnancy was not achieved after embryo transfer. In the third patient, a submucosal myoma was detected and a third HM was performed; follow-up HSG showed no IUA, and embryo transfer resulted in a biochemical pregnancy. Overall, 6 (12%) patients developed IUA. No cases of massive bleeding, uterine perforation, or fluid overload were observed. Conclusion: HM appears to be a safe and reliable method in the treatment of FIGO type 0, I, and II myomas and may improve the pregnancy outcomes when performed before embryo transfer.

  • Open Access

    Inverted microscopy as a high performance tool for pre denudation evaluation of oocyte nuclear maturity

    by Nuri Peker, Ayşen Yücetürk, Özge Karaosmanoğlu, Esra Tığlı, Burak Elmas, İlKe Özer Aslan, Sadık Doğan, Bülent Tıraş

    Inverted microscopy as a high performance tool for pre denudation evaluation of oocyte nuclear maturity - Turkish Journal of Obstetrics and Gynecology